LeonaBio director receives 28,000 stock options

LeonaBio, Inc. director Barbara Kosacz received a grant of stock options representing rights to buy 28,000 shares of common stock.

Rhea-AI Filing Summary

LeonaBio, Inc. director Barbara Kosacz received a grant of stock options representing rights to buy 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.

According to the grant terms, the 28,000 option shares are scheduled to vest in equal monthly installments over 24 months from the grant date, as long as Kosacz continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.

Insights

Equity compensation analyst

Routine director stock option grant with time-based vesting.

Director Barbara Kosacz received 28,000 stock options in LeonaBio, Inc. at an exercise price of $9.54 per share, expiring on April 8, 2036. The filing characterizes this as a grant or award, not an open-market purchase.

The options vest monthly over 24 months, contingent on continued status as a Service Provider under the 2026 Equity Incentive Plan. This structure aligns incentives over a two-year period and is typical for equity-based director compensation rather than a directional trading signal.

The filing shows 28,000 derivative securities held following the transaction, matching the grant size and indicating this is a new, routine award. There is no accompanying sale or tax-withholding transaction in this report.

Insider Trade Summary

Grant/Award: 28,000 shares

Grant/Award 1 txn

Insider Kosacz Barbara

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	28,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 28,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.

Key Figures

Stock options granted: 28,000 options Exercise price: $9.54 per share Options held after grant: 28,000 derivative securities +2 more

5 metrics

Stock options granted 28,000 options Grant to director Barbara Kosacz

Exercise price $9.54 per share Stock Option (Right to Buy) grant

Options held after grant 28,000 derivative securities Total options following transaction

Option term Expires April 8, 2036 Expiration date of granted options

Vesting schedule 24 monthly installments Monthly vesting over 24 months from grant

Key Terms

Stock Option (Right to Buy), 2026 Equity Incentive Plan, Service Provider, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

2026 Equity Incentive Plan financial

"as defined in the Issuer's 2026 Equity Incentive Plan"

Service Provider financial

"subject to the optionee continuing to be a Service Provider"

vesting financial

"scheduled to vest monthly over a term of 24 months"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LeonaBio director Barbara Kosacz report in this Form 4?

Barbara Kosacz reported receiving a grant of stock options for 28,000 shares of LeonaBio common stock. These options were awarded at an exercise price of $9.54 per share, providing the right to buy shares in the future rather than reflecting an open-market stock purchase.

How many LeonaBio stock options were granted to Barbara Kosacz?

The filing shows a grant of 28,000 stock options to director Barbara Kosacz. Each option represents the right to buy one share of LeonaBio common stock, subject to vesting conditions and an exercise price of $9.54 per share set on the grant date.

What is the exercise price and expiration date of Barbara Kosacz’s LeonaBio options?

The granted stock options carry an exercise price of $9.54 per share and expire on April 8, 2036. This means Kosacz can choose to exercise vested options at $9.54 any time before that expiration date, according to the plan’s and grant’s terms.

How do the LeonaBio options granted to Barbara Kosacz vest over time?

The 28,000 options are scheduled to vest in monthly installments over 24 months from the grant date. Vesting requires that Kosacz continues to be a Service Provider under LeonaBio’s 2026 Equity Incentive Plan through each applicable monthly vesting date.

Does this LeonaBio Form 4 show any stock sales or open-market purchases?

No, this Form 4 only reports a grant of stock options classified as a grant, award, or other acquisition. There are no open-market stock purchases or sales disclosed, and the transaction is purely equity compensation rather than a trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/13/2026 - 04:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kosacz Barbara

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.54	04/09/2026		A		28,000		(1)	04/08/2036	Common Stock	28,000	$0	28,000	D

Explanation of Responses:

1. The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.

	/s/ Mark Worthington, Attorney in fact for Barbara Kosacz	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)